Evidence map›Paper›PMID 30125678›Full record

ReviewDrug discovery today2019

Advancing precision medicine with personalized drug screening.

Kirill Gorshkov, Catherine Z Chen, Raisa E Marshall, Nino Mihatov, Yong Choi, Dac-Trung Nguyen, Noel Southall, Kevin G Chen, John K Park, Wei Zheng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug discovery today, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Biomaterials science · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. 3D Bioprinting for Next-Generation Personalized Medicine.International journal of molecular sciences · 2023
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Kirill GorshkovNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892-3375, USA.
Catherine Z ChenNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892-3375, USA.
Raisa E MarshallNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-3375, USA.
Nino MihatovNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-3375, USA.
Yong ChoiNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-3375, USA.
Dac-Trung NguyenNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892-3375, USA.
Noel SouthallNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892-3375, USA.
Kevin G ChenNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-3375, USA.
John K ParkNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-3375, USA.
Wei ZhengNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892-3375, USA. Electronic address: wzheng@mail.nih.gov.
National Institutes of Health · US

Funding

Drug Repurposing Screening for Rare and Neglected DiseasesZIATR000018 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI ZHENG, WEI · 2015 to 2025
$24.6M
Intramural NIH HHS ZIA TR000018
6 · The paper itself

Abstract

Personalized drug screening (PDS) of approved drug libraries enables rapid development of specific small-molecule therapies for individual patients. With a multidisciplinary team including clinicians, researchers, ethicists, informaticians and regulatory professionals, patient treatment can be optimized with greater efficacy and fewer adverse effects by using PDS as an approach to find remedies. In addition, PDS has the potential to rapidly identify therapeutics for a patient suffering from a disease without an existing therapy. From cancer to bacterial infections, we review specific maladies addressed with PDS campaigns. We predict that PDS combined with personal genomic analyses will contribute to the development of future precision medicine endeavors.

Indexed as

Drug Evaluation, PreclinicalPrecision MedicineDrug RepositioningHumans

Identifiers

PMID30125678
PMCPMC6372320
OpenAlexW2887850845

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.